CARLSBAD, Calif.–(BUSINESS WIRE)–Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner Novartis today announced that the pelacarsen Phase 3 Lp(a)HORIZON study, a pioneering cardiovascular outcomes trial, did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization, compared to placebo. Consistent with previous studies, substan
Coronary/Structural Heart
InnovHeart Announces First U.S. Saturn Transseptal TMVR System Implant, Reaching 15 Patients Globally
NEWTON, Mass. and MILAN, Sept. 3, 2026 /PRNewswire/ — InnovHeart, a medical device company developing the Saturn Transseptal Transcatheter Mitral Valve Replacement (TMVR) System, today announces the successful implantation of the first U.S. patient with the Saturn system as part of the…
Cleerly Announces New Findings on How AI-QCT Plaque Measurements Relate to Long-Term Cardiovascular Risk
DENVER–(BUSINESS WIRE)– #AI–Cleerly, a leader in advanced cardiovascular imaging analysis, today announced findings from a study of 1,385 patients with suspected coronary artery disease (CAD) presented at the European Society of Cardiology (ESC) Congress 2026 in Munich. The study, titled “Temporal associations of coronary plaque burden and myocardial perfusion with clinical outcomes,” was led by Jorge Dahdal, MD, of Clínica Alemana de Santiago, Chile, and Amsterdam UMC, the Netherlands, and presen
Medtronic Announces Strategic Investment in Pi-Cardia to Accelerate Innovation for Complex TAVR
GALWAY, Ireland and REHOVOT, Israel, Sept. 1, 2026 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, and Pi-Cardia Ltd., a pioneer in leaflet modification technologies for structural heart disease, today announced a strategic investment by Medtronic in…
Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026
New single-arm, open-label data extend the body of evidence supporting consistent clinical benefit and safety with Camzyos, adding to the longest-running clinical development experience for a cardiac myosin inhibitor (CMI) in symptomatic oHCM Additional presentations at ESC Congress build upon the established effectiveness and safety profile of Camzyos in real-world settings PRINCETON, N.J.–(BUSINESS […]
Lapsi Health and the Mexican Society of Cardiology Announce Strategic Collaboration to Expand Access to Cardiovascular Clinical Guidance Through Keikku
AMSTERDAM & MEXICO CITY–(BUSINESS WIRE)–Lapsi Health, the clinical AI company behind the Keikku AI Clinical Platform, and the Sociedad Mexicana de Cardiología (SMC) today announced a strategic clinical, scientific and educational collaboration designed to make trusted cardiovascular guidance more accessible to healthcare professionals in Mexico. Through the collaboration, mutually identified clinical guidelines, consensus statements, clinical recommendations, scientific guidance and other edu
Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure
Findings presented at ESC Congress 2026 and simultaneously published in JACC: Heart FailureTHE WOODLANDS, Texas, Aug. 31, 2026 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced results from a post hoc analysis of the Phase 3 SOLOIST-WHF trial evaluating the efficacy and safety of sotagliflozin across the spectrum of baseline systolic blood pressure in patients recently hospitalized for worsening heart failure. The data, which were presented yesterday at ESC Congress 2026 in Munich, Germany and simultaneously published in JACC: Heart Failure1, demonstrated that the results of sotagliflozin treatment were maintained regardless of baseline systolic blood pressure. Among patients with baseline systolic blood pressure as low as 100 mmHg, treatment with sotagliflozin was associated with a reduction in cardiovascular death and heart failure-related events, without an increase in hypotension or acute kidney injury (AKI). “Patients hospitalized for recent worsening heart failure and lower systolic blood pressure are often considered among the most clinically vulnerable,” said Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer. “We were encouraged to see that the results of sotagliflozin treatment remained consistent across the spectrum of baseline blood pressure in SOLOIST-WHF, providing additional insight into the potential utility of sotagliflozin in a particularly high-risk heart failure population.” The SOLOIST-WHF trial randomized 1,222 patients with type 2 diabetes admitted for worsening heart failure to treatment with the dual SGLT 1 and 2 inhibitor sotagliflozin or placebo. The analysis demonstrated that the effect of sotagliflozin was consistent across the spectrum of baseline systolic blood pressure (SBP), with no evidence that treatment effect varied by baseline blood pressure. Among patients with a baseline SBP
Arch Biopartners Receives Central IRB Approval to Support U.S. Sites in Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial of LSALT Peptide
TORONTO, Aug. 31, 2026 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF) today announced that it has received central Institutional Review Board (“IRB”) approval of the protocol and related study documents for the Company’s ongoing Phase II trial of LSALT peptide targeting cardiac surgery-associated acute kidney injury (“CS-AKI”). Arch recently announced that the Company will expand the study into the United States following interest from clinicians at five leading institutions. The central IRB approval completes an important step toward activating these U.S. sites. It provides an ethical review that participating sites may use instead of their local institutional review board to accelerate the site activation process. The planned U.S. arm of the study builds on progress achieved at the trial’s existing clinical sites in Canada and past sites in Turkey. The expansion into the U.S. is intended to increase the trial’s visibility in the global healthcare sector and broaden patient recruitment. The Company is also continuing to grow the trial in Canada as one additional Canadian site moves through the activation process. “The U.S. expansion is an important part of our development strategy for LSALT peptide and the CS-AKI program,” said Richard Muruve, Chief Executive Officer of Arch Biopartners. “For Arch, it is also a strategic step toward establishing a stronger global presence as we advance our clinical-stage kidney programs.” The Company expects new U.S. clinical sites to require four to six months to complete site preparation, contracting, regulatory review, training and other start-up activities before dosing their first patients. Some of these activities are already underway with prospective U.S. sites. Timing will vary by institution and is subject to the completion of all applicable approvals. About the CS-AKI Phase II Trial Cardiac surgery-associated acute kidney injury is a common complication following on-pump (heart-lung machine) cardiac surgery and can lead to longer hospital stays and worse outcomes. The trial is designed to evaluate whether LSALT peptide can reduce the rate of AKI in this setting. The CS-AKI Phase II trial is a multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide with a recruitment target of 240 patients. The primary objective of the trial is to evaluate the percentage of subjects with acute kidney injury within seven days following on-pump cardiac surgery, as defined by the KDIGO (Kidney Disease: Improving Global Outcomes) criteria. Details of the Phase II trial can be viewed at ClinicalTrials.gov: NCT05879432. About Arch Biopartners Arch Biopartners Inc. is a therapeutic biotechnology company developing on-target drugs for acute kidney injury (AKI) and chronic kidney disease (CKD). The Company is advancing an integrated program that includes new treatments targeting inflammation- and toxin-related kidney injury. Arch’s development pipeline includes: LSALT peptide: in a Phase II trial targeting cardiac surgery-associated AKI.Cilastatin: a repurposed drug in a Phase II trial targeting toxin-induced AKI.CKD Platform: next-generation therapeutics targeting chronic kidney disease. These assets represent distinct, mechanism-based approaches focused on protecting the kidney from common causes of acute and chronic damage. Chronic kidney disease affects more than 800 million people worldwide,1 while acute kidney injury adds a further significant burden. Together, Arch’s programs target unmet needs across both acute and chronic kidney disease. Both Phase II programs are currently enrolling patients at Canadian clinical sites, with an additional Canadian site in development and a U.S. expansion of the CS-AKI trial underway. For more details about the Company’s science and ongoing clinical trials, please visit www.archbiopartners.com/our-science Follow Arch on LinkedIn, Bluesky, and X (formerly Twitter) for company updates and scientific content. The Company has 67,933,289 common shares outstanding. For more information, please contact: Aaron BensonDirector of CommunicationsArch Biopartners Inc. 647-428-7031 Send a message or subscribe for updates at www.archbiopartners.com/contact-us Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable Canadian securities laws regarding expectations of the Company’s future performance, liquidity, and capital resources, as well as the ongoing development of its drug candidates targeting chronic kidney disease and the dipeptidase-1 (DPEP1) pathway, including the outcomes of its clinical trials relating to LSALT peptide (Metablok) and cilastatin, the successful commercialization and marketing of its drug candidates, whether the Company will receive, and the timing and costs of obtaining, regulatory approvals in Canada, the United States, Europe, and other countries, its ability to raise capital to fund its business plans, the efficacy of its drug candidates compared to the drug candidates developed by competitors, its ability to retain and attract key management personnel, and the breadth of, and its ability to protect, its intellectual property portfolio. These statements are based on management’s current expectations and beliefs, including certain factors and assumptions, as described in the Company’s most recent annual audited financial statements and related management’s discussion and analysis under the heading “Business Risks and Uncertainties”. As a result of these risks and uncertainties, or other unknown risks and uncertainties, actual results may differ materially from those contained in any forward-looking statements. The words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company undertakes no obligation to update forward-looking statements, except as required by law. Additional information relating to Arch Biopartners Inc., including the Company’s most recent annual audited financial statements, is available by accessing the Canadian Securities Administrators’ System for Electronic Document Analysis and Retrieval (“SEDAR+”) website at www.sedarplus.ca. References: Mark, Patrick B., et al. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. The Lancet, 2025;406(10518), 2461–2482. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01853-7/fulltext Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026
Presentations Expand Understanding of Treatment Adherence, Long-Term Outcomes, Lipoprotein(a), Coagulation Biomarkers, and Potential Mechanisms of Eicosapentaenoic Acid (EPA) 2026 ESC/European Renal Association (ERA) Cardiovascular and Chronic Kidney Disease Guideline Further Reinforces the Clinical Evidence Supporting Icosapent Ethyl DUBLIN and BRIDGEWATER, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today highlighted findings from multiple Amarin supported presentations at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany. The research presented by leading academic collaborators further expanded understanding of treatment adherence, long-term cardiovascular outcomes, lipoprotein(a) [Lp(a)] biology, coagulation biomarkers and potential mechanistic pathways associated with eicosapentaenoic acid (EPA) and icosapent ethyl (IPE). The presentations build upon the significant body of evidence generated from REDUCE-IT and related scientific investigations. “The research presented at ESC Congress 2026 demonstrates the continued scientific value of REDUCE-IT and the breadth of insights that can be gained through ongoing clinical and mechanistic investigation,” said Deepak L. Bhatt, M.D., M.P.H., M.B.A., Director of Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Medicine at the Icahn School of Medicine at Mount Sinai. “These studies advance our understanding of important factors that influence residual cardiovascular risk, including lipoprotein(a) biology, treatment adherence, sex-related differences in study participation, and coagulation pathways. At the same time, mechanistic research continues to provide new insights into how EPA may favorably influence biological processes associated with cardiovascular disease. Despite meaningful progress in cardiovascular prevention, substantial residual risk remains for many patients, underscoring the importance of utilizing proven, complementary therapies as part of a comprehensive treatment strategy. Collectively, these findings further strengthen the body of scientific evidence supporting the role of icosapent ethyl in helping reduce cardiovascular risk in appropriately selected patients.” In addition, the recently published 2026 dedicated ESC Guidelines for the Management of Cardiovascular Disease and Chronic Kidney Disease, developed with the ERA, recognize evidence from the REDUCE-IT RENAL publication showing that icosapent ethyl reduced major adverse cardiovascular events in statin-treated patients with established ASCVD, elevated triglycerides, and chronic kidney disease.i Relative risk reductions were consistent across subgroups divided by estimated glomerular filtration rate (eGFR) at baseline, with absolute benefits largest in patients with eGFR
New Data at ESC Congress 2026 Validate Caristo’s FAI-Score™ Biomarker and Highlight Potential Non-Contrast Cardiac CT Opportunity
—Independent Oxford-led data showcase the value of coronary inflammation assessment in non-contrast cardiac CT, identifying risk even in patients with zero coronary calcium— —Late-breaking ORFAN-MAESTRIA data and additional investigator-led analyses highlight broader scientific…



